Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
116
mi
from 43215
Middleburg Heights, OH
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
116
mi
from 43215
Middleburg Heights, OH
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
508
mi
from 43215
Memphis, TN
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
508
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1778
mi
from 43215
Spokane, WA
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Research Site
5386
mi
from 43215
Ciudad Autónoma de Buenos Aires,
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Research Site
5386
mi
from 43215
Ciudad Autónoma de Buenos Aires,
Click here to add this to my saved trials
A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
Status: Enrolling
Updated:  12/31/1969
Therapeutics Clinical Research
1947
mi
from 43215
San Diego, CA
A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
Status: Enrolling
Updated: 12/31/1969
Therapeutics Clinical Research
1947
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
Status: Enrolling
Updated:  12/31/1969
DermResearch, Inc.
1059
mi
from 43215
Austin, TX
A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
Status: Enrolling
Updated: 12/31/1969
DermResearch, Inc.
1059
mi
from 43215
Austin, TX
Click here to add this to my saved trials
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Proof-of-Concept in Psoriatic Patients
Status: Enrolling
Updated:  12/31/1969
Healthy Volunteer Site 1
472
mi
from 43215
Fair Lawn, NJ
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Proof-of-Concept in Psoriatic Patients
Status: Enrolling
Updated: 12/31/1969
Healthy Volunteer Site 1
472
mi
from 43215
Fair Lawn, NJ
Click here to add this to my saved trials
Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis
An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Taclonex Ointment With Hydrogel Patch Occlusion to Taclonex Ointment Without Occlusion in the Treatment of Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
UCSF Psoriasis and Skin Treatment Center
2109
mi
from 43215
San Francisco, CA
Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis
An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Taclonex Ointment With Hydrogel Patch Occlusion to Taclonex Ointment Without Occlusion in the Treatment of Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
UCSF Psoriasis and Skin Treatment Center
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Vitamin D Deficiency and Atopic Dermatitis
Treatment Of Vitamin D Deficiency And Effect On Atopic Dermatitis Severity
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Wisconsin
335
mi
from 43215
Milwaukee, WI
Vitamin D Deficiency and Atopic Dermatitis
Treatment Of Vitamin D Deficiency And Effect On Atopic Dermatitis Severity
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Wisconsin
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet
Status: Enrolling
Updated:  12/31/1969
UC Irvine Dermatology Clinical Research Center
1960
mi
from 43215
Irvine, CA
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet
Status: Enrolling
Updated: 12/31/1969
UC Irvine Dermatology Clinical Research Center
1960
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet
Status: Enrolling
Updated:  12/31/1969
Wake Forest University School of Medicine
306
mi
from 43215
Winston-Salem, NC
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet
Status: Enrolling
Updated: 12/31/1969
Wake Forest University School of Medicine
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet
Status: Enrolling
Updated:  12/31/1969
DBA Dermatology Associates
2007
mi
from 43215
Seattle, WA
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet
Status: Enrolling
Updated: 12/31/1969
DBA Dermatology Associates
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis
A Clinical Study Comparing the Efficacy of Ultravate Ointment Once Daily vs. Twice Daily in Combination With Lac-Hydrin Lotion in the Treatment of Stable Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
UCSF Psoriasis and Skin Treatment Center
2109
mi
from 43215
San Francisco, CA
Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis
A Clinical Study Comparing the Efficacy of Ultravate Ointment Once Daily vs. Twice Daily in Combination With Lac-Hydrin Lotion in the Treatment of Stable Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
UCSF Psoriasis and Skin Treatment Center
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
PRA Health Sciences
1512
mi
from 43215
Salt Lake City, UT
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
PRA Health Sciences
1512
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
Status: Enrolling
Updated:  12/31/1969
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
Status: Enrolling
Updated: 12/31/1969
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Human Repeated Insult Patch Test
Human Repeated Insult Patch Test
Status: Enrolling
Updated:  12/31/1969
Consumer Product Testing Company
462
mi
from 43215
Fairfield, NJ
Human Repeated Insult Patch Test
Human Repeated Insult Patch Test
Status: Enrolling
Updated: 12/31/1969
Consumer Product Testing Company
462
mi
from 43215
Fairfield, NJ
Click here to add this to my saved trials
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study Comparing Taro Product to RLD and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis
Status: Enrolling
Updated:  12/31/1969
Catawba Research, LLC
351
mi
from 43215
Charlotte, NC
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study Comparing Taro Product to RLD and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis
Status: Enrolling
Updated: 12/31/1969
Catawba Research, LLC
351
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Effects of Pimecrolimus on Skin Biopsy Ex-Plants From Patients With Atopic Dermatitis
A Pilot Ex-Vivo Study to Evaluate the Effect of Pimecrolimus on Antimicrobial Peptide Expression and Vaccinia Virus Growth in Perilesional Skin Cultures of Patients With Atopic Dermatitis
Status: Enrolling
Updated:  9/20/2006
National Jewish Medical and Research Center
1160
mi
from 43215
Denver, CO
Effects of Pimecrolimus on Skin Biopsy Ex-Plants From Patients With Atopic Dermatitis
A Pilot Ex-Vivo Study to Evaluate the Effect of Pimecrolimus on Antimicrobial Peptide Expression and Vaccinia Virus Growth in Perilesional Skin Cultures of Patients With Atopic Dermatitis
Status: Enrolling
Updated: 9/20/2006
National Jewish Medical and Research Center
1160
mi
from 43215
Denver, CO
Click here to add this to my saved trials
LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis
A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated:  11/17/2008
Mass General Hospital Clinical Unit for Research Trials in Skin
643
mi
from 43215
Boston, MA
LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis
A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated: 11/17/2008
Mass General Hospital Clinical Unit for Research Trials in Skin
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Eczema Prevention Study
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
Status: Enrolling
Updated:  12/9/2008
Oregon Health & Science University, Department of Dermatology
2027
mi
from 43215
Portland, OR
Eczema Prevention Study
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
Status: Enrolling
Updated: 12/9/2008
Oregon Health & Science University, Department of Dermatology
2027
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
Transepidermal Water Loss (TEWL) and Corneometry With Hydrogel Vehicle in the Treatment of Atopic Dermatitis - A Randomized, Investigator-Blind Pilot Study
Status: Enrolling
Updated:  2/8/2010
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
Transepidermal Water Loss (TEWL) and Corneometry With Hydrogel Vehicle in the Treatment of Atopic Dermatitis - A Randomized, Investigator-Blind Pilot Study
Status: Enrolling
Updated: 2/8/2010
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use
An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use
Status: Enrolling
Updated:  5/27/2010
Florida Academic Dermatology Center
993
mi
from 43215
Miami, FL
An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use
An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use
Status: Enrolling
Updated: 5/27/2010
Florida Academic Dermatology Center
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Status: Enrolling
Updated:  5/28/2010
Rady Children's Hospital Dermatolgoy
1947
mi
from 43215
San Diego, CA
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Status: Enrolling
Updated: 5/28/2010
Rady Children's Hospital Dermatolgoy
1947
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.
Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.
Status: Enrolling
Updated:  8/5/2010
Mount Sinai School of Medicine, Department of Dermatology, Clinical Trials
480
mi
from 43215
New York, NY
Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.
Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.
Status: Enrolling
Updated: 8/5/2010
Mount Sinai School of Medicine, Department of Dermatology, Clinical Trials
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy
Open-Label Study to Assess the Safety and Efficacy of Apremilast in Patients With Chronic Plaque Psoriasis Who Have Failed One Course of Biologic Therapy.
Status: Enrolling
Updated:  9/10/2010
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy
Open-Label Study to Assess the Safety and Efficacy of Apremilast in Patients With Chronic Plaque Psoriasis Who Have Failed One Course of Biologic Therapy.
Status: Enrolling
Updated: 9/10/2010
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis
Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  9/20/2010
Mount Sinai School of Medicine
481
mi
from 43215
New York, NY
Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis
Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 9/20/2010
Mount Sinai School of Medicine
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  9/23/2010
NYU Hospital for Joint Diseases
478
mi
from 43215
New York, NY
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 9/23/2010
NYU Hospital for Joint Diseases
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  9/23/2010
Bellevue Hospital
479
mi
from 43215
New York, NY
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 9/23/2010
Bellevue Hospital
479
mi
from 43215
New York, NY
Click here to add this to my saved trials
Cooling Pillow for Atopic Dermatitis
Novel Use of a Cooling Pillow for Treatment of Severe Hand and Neck Atopic Dermatitis
Status: Enrolling
Updated:  4/29/2011
Northwestern University Department of Dermatology
274
mi
from 43215
Chicago, IL
Cooling Pillow for Atopic Dermatitis
Novel Use of a Cooling Pillow for Treatment of Severe Hand and Neck Atopic Dermatitis
Status: Enrolling
Updated: 4/29/2011
Northwestern University Department of Dermatology
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Text Messaging and Atopic Dermatitis
The Use of Text Messages to Improve Adherence to Health Maintenance Behaviors in Adolescents With Atopic Dermatitis
Status: Enrolling
Updated:  4/29/2011
Northwestern University, Feinberg School of Medicine, Department of Dermatology
274
mi
from 43215
Chicago, IL
Text Messaging and Atopic Dermatitis
The Use of Text Messages to Improve Adherence to Health Maintenance Behaviors in Adolescents With Atopic Dermatitis
Status: Enrolling
Updated: 4/29/2011
Northwestern University, Feinberg School of Medicine, Department of Dermatology
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Text Messaging and Atopic Dermatitis
The Use of Text Messages to Improve Adherence to Health Maintenance Behaviors in Adolescents With Atopic Dermatitis
Status: Enrolling
Updated:  4/29/2011
Ann & Robert H. Lurie Children's Hospital of Chicago
274
mi
from 43215
Chicago, IL
Text Messaging and Atopic Dermatitis
The Use of Text Messages to Improve Adherence to Health Maintenance Behaviors in Adolescents With Atopic Dermatitis
Status: Enrolling
Updated: 4/29/2011
Ann & Robert H. Lurie Children's Hospital of Chicago
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
Status: Enrolling
Updated:  5/25/2011
University of California, Davis Department of Dermatology
2042
mi
from 43215
Sacramento, CA
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
Status: Enrolling
Updated: 5/25/2011
University of California, Davis Department of Dermatology
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants
A Randomized Pilot Trial Comparing Cetaphil® Restoraderm® System and Standard Skin Care in Infants at Risk for Atopic Dermatitis
Status: Enrolling
Updated:  6/20/2011
Oregon Health & Science University Center for Health & Healing
2027
mi
from 43215
Portland, OR
Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants
A Randomized Pilot Trial Comparing Cetaphil® Restoraderm® System and Standard Skin Care in Infants at Risk for Atopic Dermatitis
Status: Enrolling
Updated: 6/20/2011
Oregon Health & Science University Center for Health & Healing
2027
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Status: Enrolling
Updated:  2/13/2012
VA Medical Center, Cleveland
129
mi
from 43215
Cleveland, OH
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Status: Enrolling
Updated: 2/13/2012
VA Medical Center, Cleveland
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Status: Enrolling
Updated:  2/13/2012
University Hospital Case Medical Center
129
mi
from 43215
Cleveland, OH
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
Status: Enrolling
Updated: 2/13/2012
University Hospital Case Medical Center
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Tolerability of Narrow Band UVB Phototherapy in Enhancing Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  2/24/2012
UCSF Psoriasis and Skin Treatment Center
2109
mi
from 43215
San Francisco, CA
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Tolerability of Narrow Band UVB Phototherapy in Enhancing Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 2/24/2012
UCSF Psoriasis and Skin Treatment Center
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
A Comparison of Treatment of Psoriasis With Acitretin or Tazarotene Gel 0.1% and Active or Sham Treatments With the 308 nm Excimer Laser
Status: Enrolling
Updated:  3/6/2012
University of Utah Department of Dermatology
1511
mi
from 43215
Salt Lake City, UT
Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
A Comparison of Treatment of Psoriasis With Acitretin or Tazarotene Gel 0.1% and Active or Sham Treatments With the 308 nm Excimer Laser
Status: Enrolling
Updated: 3/6/2012
University of Utah Department of Dermatology
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
522
mi
from 43215
Bridgeport, CT
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
522
mi
from 43215
Bridgeport, CT
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
749
mi
from 43215
Daytona Beach, FL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
749
mi
from 43215
Daytona Beach, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
797
mi
from 43215
Metairie, LA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
797
mi
from 43215
Metairie, LA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
643
mi
from 43215
Boston, MA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
559
mi
from 43215
Rochester, MN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
Click here to add this to my saved trials